Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant
cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase
program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Even the most steady and stalwart of tools in the content marketer's arsenal — the editorial calendar — has transformed itself
over the years, from a simple spreadsheet for tracking what we publish to an essential component for managing the entire life
cycle of our organization's content marketing
program.
27 % of high growth firms (
over 20 % revenue growth) reported that an employee advocacy
program shortened their sales
cycle.
Setting your editorial calendar: This most steady and stalwart of tools in the content marketer's arsenal has transformed itself
over the years, from a simple spreadsheet for tracking what we publish to an essential component for managing the entire life
cycle of our organization's content marketing
program.
I was put on an exercise
program by one of my professors which really helped, and we worked up from
cycling on a reclining bike for 2 minutes to going on the cross trainer for 45 minutes
over the course of about nine months.
With the addition of Oregon, NICA now has the infrastructure in place to serve just
over 60 % of the country's population; we are well on our way towards fulfilling our mission of providing every American teenager the opportunity to participate in NICA
programming through a school or community based
cycling team.»
Levine, another Manhattan Democrat who also did not participate in the public funds
program, raised $ 439,110
over the course of the election
cycle.
U.S. Chamber of Commerce: The Chamber's political
program has become increasingly sophisticated
over the past few
cycles, and given the organization's reach into local groups across the country, it is sure to be a major factor in 2006.
The new
program checks some key political boxes for the mayor: it effectively allows de Blasio to highlight and expand the cleanest political win of his administration repeatedly
over the election
cycle, while still being able to claim that he's rolled out new education plans since the November 2015 announcement of his equity and excellence agenda.
In the first funding
cycle of the ADVANCE
program, nine universities and colleges were awarded as much as $ 4 million
over a period of 5 years.
Building on its BP Solar business — which BP expects to hit revenues of $ 1 billion in 2008 — BP Alternative Energy manages an investment
program in solar, wind, hydrogen and combined
cycle gas turbine power generation, which the company predicts could amount to $ 8 billion
over the next 10 years.
Your readers should know, however, that the cost
over the life
cycle of the
program has been estimated to be $ 1.4 trillion, more than 3.5 times greater than the Department of Defense's recent
program cost estimate of $ 391.1 billion, which is reported in your graphic.
Over the course of evolution, organisms have developed variations in their cell
cycle programs to be able to generate and maintain a plethora of different cell types and tissues.
Over the years, Ms. Eisenhower has served as a member of three blue ribbon commissions for the Department of Energy for three different secretaries: The Baker - Cutler Commission on U.S. Funded Non-Proliferation
Programs in Russia; The Sununu - Meserve Commission on Nuclear Energy; and the Blue Ribbon Commission on America's Nuclear Future, which released its findings on a comprehensive
program for the back end of the nuclear fuel
cycle in the winter of 2012.
As part of a Head in the Clouds
program with AWS,
Cycle Computing, and Intel, NASA is leveraging cloud computing to study the carbon stored in trees and bushes
over the Sahara.
In fact, in it's entirety this
program is, essentially, a classic 12 - week periodized
program similar in spirit to Hypertrophy Specific Training, though more gently and less rigidly ramping up
over a longer training
cycle.
of starting the
cycling seeds
program for hormonal balance, I got my first period in
over 3 years.
What about a macro balance
over several days with carb and calorie
cycling on training days (as is seen in many
programs)?
this
program is
over training even for the average steroid user the chest routine is great though no questions asked the best chest workout i have ever done but everything else is just a bit much you will lose muscle and weight if you are not taking in at least 1.5 gram of protien for every pound you way and are not running multiple compounds in a
cycle
According to the nonpartisan Legislative Fiscal Bureau (LFB), the voucher
program is estimated to cost Wisconsin taxpayers
over $ 1.1 billion between 2011 and the end of the current two - year budget
cycle in 2017.
Only about 46 percent of children aged three through six in families below the federal poverty line are enrolled in center - based early childhood
programming, compared to 72 percent of children in families above the federal poverty line.1 Poor children are about 25 percent less likely to be ready for school at age five than children who are not poor.2 Once in school, these children lag behind their better - off peers in reading and math, are less likely to be enrolled in college preparatory coursework, less likely to graduate, and
over 10 percent more likely to require remediation if they attend a four - year post-secondary institution.3 All of these issues compound one another to create a
cycle of low opportunity: children in poverty are less likely to achieve high educational attainment, and low educational attainment leads to lower median weekly earnings and higher rates of unemployment.
According to the nonpartisan Legislative Fiscal Bureau, the voucher
program will cost Wisconsin taxpayers
over $ 1.1 billion from 2011 through the end of the 2015 - 17 budget
cycle.
The government has shown this change in objectives in that «the number of magnet schools that receive MSAP [Magnet Schools Assistance
Program] funding has declined in recent grant
cycles because the overall funding level has remained stagnant and not adjusted for inflation at just
over $ 100 million» (Frankenberg et al., 15).
One solution described in detail at The Humane Society's Web page describes the Trap - Neuter - Release
program (TNR) with recommendations on safe and effective ways to alleviate
over population among these feral cat colonies thereby ending unnecessary
cycles of suffering from
over breeding).
The Treasure Island Art
Program shall be developed
over a twenty - year period linked to the funding and construction
cycle of the island, following the plan's approval on June 14, 2017.
Over the course of nineteen weeks, a total of four alumni of the Museum's Artist Studios
Program — Xenobia Bailey, Maria Hupfield, LJ Roberts, and Sarah Zapata — will be invited back to MAD for two
cycles of micro-residencies, with two artists working in the gallery at a time.
Motivate will also be expanding bike share in the Bay Area to a 7,000 bike
program called Ford GoBike this year. www.motivateco.com Motivate technology powers
over 56,000 bikes on 4 continents in bike share
programs including Santander
Cycle Hire (London, UK), Bixi (Montreal, Canada), ADCB Bikeshare (Abu Dubai, UAE) and Melbourne Bike Share (Melbourne, Australia), and already provides the hardware and software for many of the bike share networks that Motivate operates.
Climate engineering
programs are completely disrupting natural weather and climate
cycles all
over the world, destroying the ozone layer, and decreasing the overall hydrological
cycle (which, in turn, fuels record drought and firestorms).
London Shells Out Money to Promote
Cycling As part of the $ 975 million USD London plans to spend on walking and
cycling programs over the next decade, London Mayor Boris Johnson has launched the «Summer of
Cycling» with the simple but important aim of
The length of time that a firm remains in one of the above governance
cycles depends, to a greater or lesser degree, upon: the firm's economics; its culture; the traditional method of admitting partners - through the firm's career development
program, lateral hires or combination; the method of allocating profits to the partners and how the system is administered; the personal characteristics, the rainmaking and professional skills of partners whose practice areas are profitable
over an extended period of time; and how certain of the more influential partners are perceived by other influential partners.
2 Pt Credit - Remedial Driving Class - 2 Pt Credit Remedial Driving Class - Air Bags - All Ages - All Courses & Instruction State Approved - All Risks - Auto Insurance - All Risks — All Ages — Auto Insurance Available - BBB Accredited Business - Bonding & Insurance - Complete Driving Record Instantly - Discounts Multi-Car - for Nervous Beginner - for Nervous Beginners - for
Over 90 Years - Gift Certificates Available for All Areas of Service - Good Drivers - Hit Skip - Hit - Skip - Immediate Coverage - In - Car Training - In - Class & In - Car Training - In Class & In CAN Training - In - Car Training - In - Class & In - Car Training - Independent Insurance Agent - Juvenile Driver Intervention
Program Available - License Back In One Day - Low Down Payments - Low Monthly Payments - Online Course Drivers Welcome -
Over 90 Years - Paypal - Point Suspension - Remedial Driving Course - Sr 22 Filing - Stop for Auto or
Cycle Insurance - Teens & Adults - When You Need A Bond Quickly
Over thirteen years experience with
programs incorporating full software development and project life
cycle processes with 2 years experience in Agile and more than 10 years in Waterfall methodologies.
Career Summary: SQL Developer and Application Integrator with
over 12 year's experiences with industry - leading organizations, who has performed full life
cycle of design, development, implementation, maintenance and analysis while utilizing strong business and
programming skills towards every assignment.
With
over 10 years of ERP deployment projects, data conversions, technical designs, and hands on configuration,
program conversions, upgrades, full life
cycle implementations and integration.
Summary: *
Over 13 years of Information Technology industry experience in analysis, design, testing and implementing Object Oriented
Programming Concepts (OOPS), Service Oriented Architecture (SOA) based Applications, client - server applications, N - tier applications, Windows Services based applications * Managed software project life
cycle such as requirement gathering, analysis, design specifications preparation, developmen...
The Training Intensive two week Director - Led Training
program Tried and tested theoretical and practical training Covering ass aspects of the Recruitment
Cycle Sales training, Sector learning, database and channel sourcing training Ongoing training through your career German lessons where required The role Recruitment Consultant; Dealing with medium to Global Blue - chip clients across Germany Working in the fast paced, dynamic Contracts technology market Work with the top future Tech experts Dealing with Digital professionals and Developers Placing with FinTech, Banking, FMCG, Automotive, Consulting companies The Company Rapid Growth business taking
over the sector and making waves across Europe Fun, buzzy, high performing sales professionals Looking for future leaders The Rewards $ 30,000 $ 35,000 base salary 1st yr earnings of $ 50,000 + Best commission structure in Berlin Potential share scheme Incentives, lunches, trips Rapid promotion for successful individuals The Infrastructure Top of the range database Big marketing and ad spend Professional Networking licenses Modern offices in top location Access to market leading analytics software The Future The company will triple in size in the next 12 mths Opportunities for new leaders t come through Chance to build new teams, divisions and global locations Opportunity to be a shareholder TO BE CONSIDERED FOR THIS SUNDAY TIMES FASTTRACK 100 COMPANY APPLY TODAY FOR IMMEDIATE CONSIDERATION, DECEMBER OR JANUARY INTERVIEW AND FEBRUARY 2018 GRADUATE SCHEME INDUCTION Also Recruiting for: Senior consultant, Berlin, Germany, Billing Manager, Berlin, Germany, Non-billing Manager / Associate Director, Berlin, Germany, Graduate Trainee London, Graduate Trainee Frankfurt, Germany.
That where the Commonwealth funds Aboriginal and Torres Strait Islander alcohol treatment and support
programs, these are funded
over a longer
cycle for at least four years, particularly for well - established and successful
programs.
The
program requires Realtors to accumulate 18 professional development credits
over a two - year
program cycle.